XSHE
002626
Market cap1.43bUSD
Oct 09, Last price
15.89CNY
1D
1.53%
1Q
16.07%
Jan 2017
14.40%
IPO
121.08%
Name
Xiamen Kingdomway Group Co
Chart & performance
P/E
28.51
P/S
2.88
EPS
0.56
Div yield, %
2.56%
Shrs. gr., 5y
0.83%
Rev. gr., 5y
-1.43%
Revenues
3.37b
+3.87%
Net income
340m
-0.61%
CFO
556m
+6.69%
Dividend
Jun 10, 20260.4 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Xiamen Kingdomway Group Company operates as a global producer and distributor of a variety of nutritional and health-focused goods. The company's offerings encompass a selection of fundamental raw ingredients, notably coenzyme Q10, Vitamin A, Vitamin D3, DHA derived from microalgae, and plant-based ARA. Furthermore, it manufactures ready-to-use dietary supplements and specialized sports nutrition products. Originally established in 1997, the firm was previously recognized as Xiamen Jindawei Vitamin Co., Ltd., and maintains its principal offices in Xiamen, China.
Key people
Jialiang Chen
Executive Deputy General Manager, Director · since 2013
Yan Hong
Secretary of the Board, Deputy General Manager · since 2011
Hang Hong
Chief Financial Officer, Deputy General Manager · since 2016
Guanghuang Zhan
Deputy General Manager
Shuilu Zhang
Deputy General Manager
Bin Jiang
Chairman of the Board, General Manager
Guoqing Ma
Deputy General Manager, Director · since 2016
Headquarters & legal address
福建省厦门市海沧新阳工业区
厦门市, FJ 361028
CN
厦门市, FJ 361028
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||